Enhanced recovery after surgery protocol and postoperative opioid prescribing for cesarean delivery: an interrupted time series analysis

• Published in: Perioperative medicine (London) Vol. 10; no. 1; p. 38
• Main Authors: Langnas, E M, Matthay, Z A, Lin, A, Harbell, M W, Croci, R, Rodriguez-Monguio, R, Chen, C L
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.11.2021; BioMed Central; BMC
• Subjects: Analgesics; Analysis; Anesthesiology; Cesarean delivery; Cesarean section; Datasets; Electronic health records; Length of stay; Medical records; Multimodal analgesia; Narcotics; Nonsteroidal anti-inflammatory drugs; Opioids; Oral morphine equivalents; Pain; Pain management; Patients; Postoperative pain; Prescription writing; Recovery (Medical); Surgery; Time series; Trends; United States > US; Cesarean delivery; Postoperative pain; Oral morphine equivalents; Multimodal analgesia; Opioids
• ISSN: 2047-0525; 2047-0525
• DOI: 10.1186/s13741-021-00209-0

Enhanced recovery after surgery (ERAS) pathways have emerged as a promising strategy to reduce postoperative opioid use and decrease the risk of developing new persistent opioid use in surgical patients. However, the association between ERAS implementation and discharge opioid prescribing practices is unclear. We conducted a retrospective observational quasi-experimental study of opioid-naïve patients aged 18+ undergoing cesarean delivery between February 2015 and December 2019 at a large academic center. An interrupted time series analysis (ITSA) was used to model the changes in pain medication prescribing associated with the implementation of ERAS to account for pre-existing temporal trends. Among the 1473 patients (out of 2249 total) who underwent cesarean delivery after ERAS implementation, 80.72% received a discharge opioid prescription vs. 95.36% at baseline. Pre-ERAS daily oral morphine equivalents (OME) on the discharge prescription decreased by 0.48 OME each month (p<0.01). There was a level shift of 35 more OME prescribed (p<0.01), followed by a monthly decrease of 1.4 OMEs per month after ERAS implementation (p<0.01). Among those who received a prescription, 61.35% received a total daily dose greater than 90 OME compared to 11.35% pre-implementation (p<0.01), while prescriptions with a total daily dose less than 50 OME decreased from 79.86 to 25.85% after ERAS implementation(p<0.01). Although ERAS implementation reduced the overall proportion of patients receiving a discharge opioid prescription after cesarean delivery, for the subset of patients receiving an opioid prescription, ERAS implementation may have inadvertently increased the prescribing of daily doses greater than 90 OME. This finding highlights the importance of early and continued evaluation after new policies are implemented.